Top Industry News

Eli Lilly and Company has agreed to acquire Centessa Pharmaceuticals, a clinical-stage bio/pharmaceutical company focused on excessive daytime sleepiness and other neurological conditions, in a deal worth up to $7.8 billion ($6.3 billion upfront and $1.5 billion in…

Merck & Co. has agreed to acquire Terns Pharmaceuticals, a clinical-stage bio/pharmaceutical company focused on oncology, for $6.7 billion.  Terns’ lead candidate, TERN-701, is an investigational oral drug for treating chronic phase chronic myeloid leukemia (CML). Specifically it…

UCB, a Brussels, Belgium-based bio/pharmaceutical company, has selected Rowen, Gwinnett County, Georgia, as the location for its new US biologics manufacturing facility. UCB announced plans to invest in the new facility in June 2025.  Spanning approximately 460,000 square…

Biogen has agreed to acquire Apellis Pharmaceuticals, a commercial-stage bio/pharmaceutical company, for $5.6 billion to expand its position in immunology, rare diseases, and nephrology (i.e., kidney disease).    The acquisition brings two commercial immunology products to Biogen: Empaveli (pegcetacoplan), FDA-approved in three indications, including two…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Novartis, Gilead Sciences, Otsuka, Merck & Co., Roche, Recordati, and Takeda. Highlights below.   M&A News * Novartis To Acquire Synnovation’s Oncology Drug in $3-Bn Deal * Gilead To Acquire Ouro Medicines…

The latest from CDMOs, CMOs, and suppliers featuring Neuland Laboratories, Cambrex, Esteve CDMO, Samsung Biologics, Lonza, Adragos Pharma, Rois, Dalton Pharma Services, Codis, Forma Life Sciences, and West Pharmaceutical Services  Appointments * Neuland Laboratories Names New CEO &…

Novo Nordisk has announced an investment of EUR 432 million ($502 million) to expand its tableting facility in Monksland, Athlone, Ireland, to produce current and future Novo Nordisk glucagon-like peptide-1 (GLP-1) treatments. It provides Novo Nordisk with additional manufacturing capabilities for…

To boost its late-stage neuroscience pipeline, Novartis has completed its $12-billion acquisition of Avidity Biosciences, a bio/pharmaceutical company developing RNA therapeutics. The deal was announced in October 2025.  Avidity is developing RNA therapeutics and antibody oligonucleotide conjugates (AOCs) for treating rare genetic neuromuscular…

GSK has completed its acquisition of RAPT Therapeutics, a South San Franciso, California-based, clinical-stage bio/pharmaceutical company, for $2.2 billion. The deal was announced in January 2026.  The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E…

The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, Flamma, BioDuro, Cenra, Bora Pharmaceuticals, Upperton, Biologos, Coating Place and more.   Chemicals/Chemical API Manufacturing * CordenPharma in Peptide Lab Expansion* Flamma API Mfg Site Passes FDA Inspection * BioDuro, Cenra API Form JV for API…